Related Experiment Videos

Damages of the mitochondrial membrane in Adriamycin treated mice

Cancer Letters
|November 1, 1984
PubMed

Insights

Adriamycin (ADM) damages heart mitochondria by increasing membrane viscosity and lipid peroxidation, inactivating respiratory enzymes. Two ADM derivatives did not cause these toxic effects in mice.

Area of Science:

  • Biochemistry
  • Toxicology
  • Cardiovascular Research

Background:

  • Adriamycin (ADM) is a widely used chemotherapy agent.
  • Cardiac toxicity is a significant concern associated with ADM treatment.
  • Mitochondrial dysfunction is implicated in ADM-induced cardiotoxicity.

Purpose of the Study:

  • To investigate the effects of ADM on mitochondrial function in the heart.
  • To determine the relationship between ADM, mitochondrial membrane properties, and enzyme activity.
  • To evaluate the cardiotoxic potential of ADM derivatives.

Main Methods:

  • Administration of ADM to OF1 Swiss mice (male and female) via intraperitoneal injection.
  • Isolation of cardiac mitochondria at 2 and 4 days post-administration.
  • Measurement of respiratory enzyme activity, mitochondrial membrane viscosity, and lipid peroxidation.

Main Results:

  • ADM treatment led to the inactivation of cardiac mitochondrial respiratory enzymes.
  • This inactivation correlated with increased mitochondrial membrane viscosity.
  • ADM also induced increased lipid peroxidation in cardiac mitochondria.
  • Two studied ADM derivatives did not exhibit these detrimental effects.

Conclusions:

  • ADM induces cardiotoxicity through mechanisms involving mitochondrial dysfunction.
  • Increased mitochondrial membrane viscosity and lipid peroxidation are key factors in ADM-induced enzyme inactivation.
  • ADM derivatives may offer a safer therapeutic profile with reduced cardiotoxic potential.

Related Concept Videos